ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

QishenYiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology

Li, Meng; Wang, Yueyao; Qi, Zhongwen; Yuan, Zhuo; Lv, Shichao; Zheng, Yawei; Yan, Zhipeng; Wang, Mingyang; Fu, Huanjie; Fan, Xinbiao; Ji, Nan; Liu, Ming*; Fang, Zhuyuan*广州中医药大学; 1
Frontiers in Pharmacology2022-9-9DOI: 10.3389/fphar.2022.981206
3被引13阅读
引用收藏
分享

摘要

Background: Myocardial ischemia/reperfusion (I/R) injury is associated with multiple serious clinical manifestations. Autophagy is upregulated in a short period of ischemia and further enhanced during reperfusion phase, which was considered as a "double-edged sword " in the pathological process of myocardial I/R injury. In addition, NLRP3 inflammasome triggers myocardial inflammatory response, which leads to cardiomyocyte death via pyroptosis and promotes subsequent myocardial remodelling. Qishen Yiqi Dripping Pill (QSYQ) has been recognized as a potential protective agent of cardiovascular diseases. Objective: We predicted the bioactive compounds, targets and pathways of OSYQ intervening on myocardial I/R injury by network pharmacology. Furthermore, we investigated the effect of QSYQ on myocardial I/R injury and explored its underlying mechanism via autophagy and NLRP3 Inflammasome. Methods: Bioactive compounds, targets of QSYQ and relevant targets of myocardial I/R injury were collected from public databases. The protein-protein interaction network, Gene ontology and KEGG pathway enrichment analysis were carried out to screen the key compounds, target genes, functional annotation and pivotal pathways. Molecular docking was used to validate the binding association between target genes and key bioactive ingredients. Furthermore, sixty SD rats were randomized into four groups: 1) sham, 2) model, 3) captopril and 4) QSYQ pretreatment (14 days before and after surgery). Each arm was subjected to ischemia/reperfusion surgery except sham arm (30 min coronary ligation, then reperfusion). Left ventricular (LV) function were evaluated and the hearts were used to evaluate size of myocardial infarction, cardiomyocyte fibrosis, and myocardial autophagosomes. Results: The network pharmacology revealed the mechanism of QSYQ intervening on myocardial I/R injury might be related to NOD-like receptor signaling pathway, PI3K-Akt signaling pathway, autophagy-animal, etc., Molecular-docking suggested the core target proteins had good binding association with bioactive compounds of QSYQ. The experiment confirmed that QSYQ attenuated myocardial infarct size, decreased inflammatory infiltration and collagen fiber deposition and alleviated the autophagosome and myocardium ultrastructure injury, leading to LV systolic function improvement. The possible mechanism of cardioprotection was due to regulating autophagy-related proteins, activating PI3K/Akt-mTOR signaling pathway, and inhibiting activation and assembly of NLRP3 inflammasome. Conclusion: QSYQ ameliorated myocardial I/R injury via suppressing excessive autophagy and NLRP3 Inflammasome.

学科与关键词

关键词
QSYQmyocardial ischemiareperfusionautophagyNLRP3 inflammasome
相关
加载中…
  • Compound Danshen Dripping Pills pretreatment protects the heart from ischemia/reperfusion injury by enhancing autophagic flux
    Liu, Haiqiong; Liang, Qian; Mei, Xiheng; Li, Hekai; Yan, Jing; Long, Man; Yang, Xili; Wang, Wei; Li, Weijie; Chen, Aihua*; Ling, Yuanna*Brazilian Journal of Pharmaceutical Sciences, 2023, 59: e211035.
  • Integrating network analysis and experimental validation to reveal the mitophagy-associated mechanism of Yiqi Huoxue (YQHX) prescription in the treatment of myocardial ischemia/reperfusion injury
    Chen, Mingtai*; Zhong, Guofu; Liu, Mengnan; Zhou, Jie; Chen, Jianping; Zhang, Mingsheng; Liu, Qiang; Tong, Guangdong; Luan, Jienan*; Zhou, Hua*; He, HaoPharmacological Research, 2023, 189: 106682.被引 5
  • Protective effect of Qingre Huoxue decoction against myocardial infarction via PI3K/Akt autophagy pathway based on UPLC-MS, network pharmacology, and in vivo evidence
    Jin, Zheng; Zhang, Wenbo; Luo, Yuan; Li, Xiushen; Qing, Lijin; Zuo, Qiang; Fang, Junfeng*; Wu, Wei*PHARMACEUTICAL BIOLOGY, 2021, 59(1): 1607-1618.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-09-09
卷期
第 13 卷
页码
981206
DOI
10.3389/fphar.2022.981206
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation; [2021M701768]

作者

  • L

    Li, Meng (第一作者)

    nanjing univ chinese med

  • W

    Wang, Yueyao

    2 · guangzhou univ chinese med

查看全部 13 位作者收起作者
  • Q

    Qi, Zhongwen

    xiyuan hosp

  • Y

    Yuan, Zhuo

    1 · tianjin univ tradit chinese med

  • L

    Lv, Shichao

    1 · tianjin univ tradit chinese med

  • Z

    Zheng, Yawei

    nanjing univ chinese med

  • Y

    Yan, Zhipeng

    tianjin univ tradit chinese med

  • W

    Wang, Mingyang

    tianjin univ tradit chinese med

  • F

    Fu, Huanjie

    tianjin univ tradit chinese med

  • F

    Fan, Xinbiao

    tianjin univ tradit chinese med

  • J

    Ji, Nan

    tianjin med univ

  • L

    Liu, Ming (通讯)

    nanjing univ chinese med

  • F

    Fang, Zhuyuan (通讯)

    nanjing univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417